Biocon and its subsidiaries Biocon Pharma and Biocon Pharma Inc. (Biocon) have entered into a confidential settlement agreement with Celgene Corporation (Celgene), a wholly owned subsidiary of Bristol Myers Squibb, relating to patents for Revlimid (lenalidomide).
Biocon is India’s largest and Asia’s leading Biotechnology Company with a strategic focus on biopharmaceuticals and research services. It is a fully integrated, innovation driven biopharma enterprise offering affordable solutions for chronic diseases to patient's worldwide.